IRIS
MASSIMINO, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.976
EU - Europa 3.368
AS - Asia 2.545
SA - Sud America 535
AF - Africa 416
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 11.848
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.811
SG - Singapore 1.301
RU - Federazione Russa 1.100
IT - Italia 912
CN - Cina 556
BR - Brasile 457
IE - Irlanda 338
VN - Vietnam 244
CI - Costa d'Avorio 232
UA - Ucraina 224
IN - India 156
DE - Germania 149
CA - Canada 126
FR - Francia 123
NL - Olanda 104
BE - Belgio 100
GB - Regno Unito 88
SN - Senegal 77
KR - Corea 62
FI - Finlandia 50
NG - Nigeria 50
BD - Bangladesh 38
SE - Svezia 35
PL - Polonia 34
AR - Argentina 30
MX - Messico 28
ES - Italia 26
IQ - Iraq 26
JP - Giappone 21
UZ - Uzbekistan 20
ZA - Sudafrica 20
TR - Turchia 19
HK - Hong Kong 17
CZ - Repubblica Ceca 15
GR - Grecia 14
CH - Svizzera 12
CO - Colombia 11
EC - Ecuador 11
ID - Indonesia 10
IR - Iran 9
KE - Kenya 9
MA - Marocco 9
PK - Pakistan 9
SA - Arabia Saudita 9
VE - Venezuela 9
AE - Emirati Arabi Uniti 8
AT - Austria 8
TN - Tunisia 8
PY - Paraguay 7
AU - Australia 6
IL - Israele 6
BG - Bulgaria 5
EG - Egitto 5
HU - Ungheria 5
KZ - Kazakistan 5
LB - Libano 5
RS - Serbia 5
AZ - Azerbaigian 4
DO - Repubblica Dominicana 4
MY - Malesia 4
NO - Norvegia 4
PE - Perù 4
RO - Romania 4
UY - Uruguay 4
BJ - Benin 3
KG - Kirghizistan 3
LT - Lituania 3
HR - Croazia 2
JM - Giamaica 2
LK - Sri Lanka 2
OM - Oman 2
PH - Filippine 2
SI - Slovenia 2
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BO - Bolivia 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
DM - Dominica 1
DZ - Algeria 1
GA - Gabon 1
GD - Grenada 1
IS - Islanda 1
JO - Giordania 1
LV - Lettonia 1
MN - Mongolia 1
NA - Namibia 1
NC - Nuova Caledonia 1
NI - Nicaragua 1
NP - Nepal 1
SK - Slovacchia (Repubblica Slovacca) 1
SR - Suriname 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 11.848
Salva come PNG Salva come JPEG
Città #
Singapore 825
Santa Clara 738
Dallas 713
Moscow 523
Chandler 443
Dublin 338
Ashburn 295
Chicago 285
San Jose 283
Catania 243
Abidjan 232
Jacksonville 219
Boardman 126
Los Angeles 120
Beijing 115
Kochi 104
Cambridge 93
Lauterbourg 92
Lawrence 91
Andover 87
Nanjing 82
Dakar 76
Hefei 69
New York 69
Toronto 65
Grafing 64
Rotterdam 64
Hanoi 63
Ho Chi Minh City 62
Seoul 61
Civitanova Marche 59
Council Bluffs 57
Wingene 50
Des Moines 48
São Paulo 48
Palermo 44
Wilmington 44
San Mateo 43
Milan 38
Buffalo 35
Orem 32
Montreal 30
Munich 30
Dong Ket 27
Warsaw 27
Brussels 26
The Dalles 23
Abuja 22
Turku 22
Columbus 21
Lagos 21
Bari 20
Ottawa 20
Rome 20
Tokyo 20
Seattle 19
Johannesburg 18
Hebei 17
Lappeenranta 17
Nanchang 17
Phoenix 17
Rio de Janeiro 17
Shenyang 17
Chennai 16
Jiaxing 16
Falls Church 15
Frankfurt am Main 15
London 15
Messina 15
Saint Petersburg 15
Belo Horizonte 14
Houston 14
Aci Catena 13
Brooklyn 13
Changsha 13
Hong Kong 13
Baghdad 12
Boston 12
Bremen 12
Denver 12
Poplar 12
Santa Venerina 12
Atlanta 11
Brasília 11
Brno 11
Helsinki 11
Manchester 11
Nijmegen 11
Stockholm 11
Tashkent 11
Amsterdam 10
Dhaka 10
Izegem 9
Mexico City 9
Pune 9
Tianjin 9
Curitiba 8
Haiphong 8
Redmond 8
Redondo Beach 8
Totale 8.041
Salva come PNG Salva come JPEG
Nome #
A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients With Diffuse Gliomas: Diagnostic and Therapeutic Applications 242
Novel mechanisms of tumor promotion by the insulin receptor isoform a in triple-negative breast cancer cells 237
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 225
Concordance between CDKN2A homozygous deletion and MTAP immunohistochemical loss in fluoroedenite-induced pleural mesothelioma: An immunohistochemical and molecular study on a single-institution series 200
A novel and selective sigma-1/2 receptor ligand (PO680C): Binding properties and expression of tissue transglutaminase 183
Activation of the IGF axis in thyroid cancer: Implications for tumorigenesis and treatment 183
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 179
DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop 171
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 168
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 167
An Optimized NGS Workflow Defines Genetically Based Prognostic Categories for Patients with Uveal Melanoma 165
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 164
Mutational Analysis of BRCA1 and BRCA2 Genes in Breast Cancer Patients from Eastern Sicily 161
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 160
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 159
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 158
Comparative proteomic analysis of insulin receptor isoform A and B signaling 156
Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity 156
A novel and selective σ1/2 receptor ligand (PO680C): binding properties and expression of tissue transglutaminase 155
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 155
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 154
B-ALL relapses after autologous stem cell transplantation associated with a shift from e1a2 to e14a2 BCR-ABL transcripts: A case report 152
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice 151
BCR-ABL TYROSINE KINASE ACTIVITY MODULATES THE PHOSPHORYLATION, LOCALIZATION AND FUNCTION OF INTERFERON REGULATORY FACTOR 5 (IRF-5) IN CHRONIC MYELOID LEUKEMIA CELLS 146
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 146
Effect of combined epigenetic treatments and ectopic NIS expression on undifferentiated thyroid cancer cells 145
Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22) 145
Diagnostic utility of the immunohistochemical expression of serin and arginine rich splicing factor 1 (Srsf1) in the differential diagnosis of adult gliomas 145
AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE 143
Discoidin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cells 143
Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells.Cancer Res 142
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 142
BCR-ABL tyrosine kinase activity modulates the phosphorylation and the localization of Interferon Regulatory Factor 5 (IRF-5)in Chronic Myeloid Leukemia cells 140
Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release 138
New insights in thyroid cancer and p53 family proteins 137
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 136
Insulin receptor isoforms differently regulate cell proliferation and apoptosis in the ligand‐occupied and unoccupied state 133
Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions 132
Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience 130
BCR-ABL TYROSINE KINASE ACTIVITY MODULATES THE PHOSPHORYLATION, LOCALIZATION AND BIOLOGICAL FUNCTION OF INTERFERON REGULATORY FACTOR 5 IN CHRONIC MYELOID LEUKEMIA CELLS 129
Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer 127
Opportunities and challenges of liquid biopsy in thyroid cancer 126
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias 125
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 125
BCR-Abl tyrosine kinase activity modulates the expression of Interferon Regulatory Factor-5 in CML cells 122
Detection and clinical implications of a novel BCR-ABL1 E12A2 insertion/deletion in a CML patient expressing the E13A2 isoform 122
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability 118
Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells 118
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib 117
Correlates of Human Herpesvirus-8 DNA detection among adults in Italy without Kaposi sarcoma 116
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far 115
BCR-ABLIS Expression at Diagnosis and After 3 or 6 Months of Treatment Predicts CML Response to IMATINIB Therapy 115
In Silico Prediction of BRCA1 and BRCA2 Variants with Conflicting Clinical Interpretation in a Cohort of Breast Cancer Patients 114
Rapid decline of philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report 113
Uncommon long-term survival in a patient with chronic myeloid leukemia 110
Computational and Experimental Characterization of Two Nuclear Localization Signals and a Nuclear Export Signal that modulate BCR intracellular localization 110
Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma 110
Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes 109
c-IAP1, Survivin and Smac contribute to chemotherapy resistance in undifferentiated thyroid cancer cells 108
Targeting BCL-2 as a therapeutic strategy for primary p210BCR-ABL1-positive B-ALL cells 107
No Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the BCR::ABL1 Transcript Level 102
Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia 101
Single-Cell Analysis in the Omics Era: Technologies and Applications in Cancer 93
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. 93
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors 92
Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase 92
UNFAVOURABLE OUTCOME OF CML PATIENTS CARRYING COMPLEX VARIANT CHROMOSOMAL TRANSLOCATIONS TREATED WITH TYROSINE KINASE INHIBITORS 92
UNA INSERZIONE NEL DOMINIO TIROSIN-CHINASICO DI BCR-ABL POTREBBE CONTRIBUIRE ALLA RESISTENZA AD IMATINIB MESILATO DI PAZIENTI AFFETTI DA LEUCEMIA MIELOIDE CRONICA 88
Diagnosis of Chronic Myeloid Leukemia Early in Pregnancy 88
FLAIRectomy in Supramarginal Resection of Glioblastoma Correlates With Clinical Outcome and Survival Analysis: A Prospective, Single Institution, Case Series 87
Espressione e funzione di OMI/HTRA2 in tumori solidi ed ematologici 85
REThinking the role of the RET oncogene in breast cancer 84
High BCR-ABL/GUS(IS) Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib 83
Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia 82
The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy 82
Ruolo delle IAPs e di Smac/DIABLO nella resistenza ai farmaci antiblastici di cellule di carcinoma indifferenziato della tiroide 82
Novel methyl-2-[4-[(4-hydroxy-4-phenylpiperidin-1-yl)methyl]-1-phenylcyclopropane-carboxylate derivatives as sigma-1 and sigma-2 receptor ligands 81
High BCR-ABL expression levels at diagnosis may predict unfavorable CML responses to Imatinib therapy 80
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance 80
Treatment with TKIs Overcomes Imatinib Resistance through the PLCgamma-1 Signaling Pathway In Imatinib Resistant Human CML Cell Lines 78
Sustained Responses and Resistance to Imatinib Mesylate in the First 173 Chronic Myeloid Leukemia Patients Accrued by the SCREEN Multicenter Study: First Interim Report 77
EFFICACY OF IMATINIB MESYLATE ON CHRONIC PHASE CML PATIENTS ACCRUED IN THE SCREEN MULTICENTER STUDY: INTERIM REPORT ON THE FIRST 193 CASES 77
Computational and biological characterization of nuclear import/export signals of the human BCR protein 76
L’attività tirosin-chinasica di BCR/Abl modula l’espressione di IRF-5 75
Experimental and Computational Characterization of Amino Acidic Residues in the BCR-ABL kinase domain contributing to TKI resistance in patients with Chronic Myeloid Leukemia 74
Molecular dynamics simulations reveal the role of five BCR-ABL kinase domain critical residues in TKIS binding 74
SYNTHESIS OF BNIT AN ISOTHIOCYANATE DERIVATIVE OF N-BENZYL-NORMETAZOCINE AS ACYLANT AGENT FOR σ1 RECEPTOR 73
High BCR-ABLIS expression at diagnosis and after 3 and 6 months of treatment are associated with unfavourable responses to Imatinib 72
High BCR-ABL/GUSIS Levels At Diagnosis Are Associated With Unfavorable Responses To Imatinib 71
THE SCREEN PROJECT: A CML DATA REGISTRY IN SICILY AND CALABRIA 70
Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis 70
Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia 69
Computational and experimental characterization of critical amino acidic residues in the BCR-ABL kinase domain explaining TKIs resistance in patients with chronic myeloid leukemia 69
HIGH BCR-ABL LEVELS AT DIAGNOSIS ARE ASSOCIATED WITH UNFAVORABLE RESPONS- ES TO IMATINIB 69
SINTESI E VALUTAZIONE FARMACOLOGICA DI DERIVATI METIL 2-[(4-BENZILPIPERIDIN-1-IL)METIL]-1-FENIL-CICLOPROPANCARBOSSILATO COME LIGANDI SIGMA AD ALTA AFFINITÀ 68
Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain 65
RAPID RESPONSE TO DASATINIB IN A CML BLAST CRISIS PATIENT THAT SUBSEQUENTLY DEVELOPED SEQUENTIAL BCR-ABL MUTATIONS CAUSING MULTI-DRUG RESISTANCE: A CASE REPORT 65
IRF5 promotes the proliferation of human thyroid cancer cells. 64
Synthesis of (+)-cis-N-(4-isothiocyanatobenzyl)-N-normetazocine, an isothiocyanate derivative of N-benzylnormetazocine as acylant agent for the sigma(1) receptor 64
HIGH DOSE IMATINIB TO ACHIEVE MOLECULAR RESPONSES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN LATE CHRONIC PHASE AND COMPLETE CYTOGENETIC RESPONSE: IS IT WORTHWHILE? 58
Totale 11.845
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.941
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.941
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021120 0 0 0 0 0 0 0 0 0 4 68 48
2021/2022686 54 97 15 9 112 13 103 27 52 14 35 155
2022/20231.373 106 102 43 153 91 214 19 263 289 11 50 32
2023/2024766 57 107 30 36 32 184 11 44 7 35 133 90
2024/20252.956 111 445 116 175 585 394 191 80 187 203 315 154
2025/20265.115 300 272 790 377 815 1.290 583 109 307 272 0 0
Totale 12.044